Abstract
Purpose
Iloperidone (Ilo) is an antipsychotic drug having low and pH-dependent solubility, hence less bioavailability. Thus, the aim of this study was to prepare and characterize binary (TAPOL B) and ternary complexes (TAPOL T) of drug with Kolliphor P-188 and tartaric acid to improve solubility. Further, sublingual tablets incorporating ternary complex were formulated to improve the dissolution.
Methods
Preliminary screening studies were conducted to select the acidifying agent and polymer based on saturation solubility studies. Binary and ternary complexes were prepared by the melting method. Complexes were characterized by DSC, powder X-ray diffraction (PXRD), FTIR, microenvironmental studies, and in vitro dissolution studies. The sublingual tablets of ternary complexes were prepared by the direct compression method and evaluated for weight variation, disintegration time, and dissolution studies.
Results
Based on solubility studies, Kolliphor P-188 and tartaric acid were selected as polymer and acidifying agents. DSC studies and FTIR spectra showed the interaction of drugs with polymer and acidifying agents. PXRD spectra showed the crystalline nature of complexes. Microenvironmental studies carried out in pH 6.8 showed a drastic decrease in pH with ternary complex as compared with binary complex. Dissolution studies showed an increase in dissolution, TAPOL T > TAPOL B > drug. The sublingual tablets showed disintegration time < 30 s and more than 80% of a drug released within 10 min. Due to the presence of tartaric acid and polymer, solubility of the drug increases tremendously.
Conclusion
The present study demonstrates the increase in solubility and release of Iloperidone due to the microenvironmental pH effect from sublingual tablets. Hence, microenvironmental pH modification is a good approach to increase drug solubility and dissolution.
Similar content being viewed by others
References
iloperidone - U.S. Food and Drug Administration Search Results [Internet]. Search.usa.gov. 2020 [cited 20 May 2020]. Available from: https://search.usa.gov/search?query=iloperidone&affiliate=fda1.
Weiden P. Iloperidone for the treatment of schizophrenia: an updated clinical Review. Clin Schizophr Relat Psychoses. 2012;6(1):34–44. https://doi.org/10.3371/csrp.6.1.5.
Breier A, Berg P. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biol Psychiatry. 1999;46(3):361–4. https://doi.org/10.1016/S0006-3223(99)00040-2.
Cheng Y, Illum L, Davis S. Schizophrenia and drug delivery systems. J Drug Target. 2000;8(2):107–17. https://doi.org/10.3109/10611860008996856.
Londhe V, Shirsat R. Formulation and characterization of fast-Dissolving sublingual film of Iloperidone using Box–Behnken design for enhancement of oral bioavailability. AAPS PharmSciTech. 2018;19(3):1392–400. https://doi.org/10.1208/s12249-018-0954-y.
Ige P, Agrawal K, Patil U. Enhanced in vitro dissolution of Iloperidone using Caesalpinia Pulcherrima mucoadhesive microspheres. Beni-Suef Univ J Basic Appl Sci. 2015;4(1):26–32. https://doi.org/10.1016/j.bjbas.2015.02.004.
Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2013;20(3):320–9. https://doi.org/10.3109/10837450.2013.867445.
Londhe V, Pawar A, Kundaikar H. Studies on spectral characterization and solubility of hydroxypropyl β-cyclodextrin/iloperidone binary and ternary complexes using different auxiliary agents. J Mol Struct. 2020;1220:128615. https://doi.org/10.1016/j.molstruc.2020.128615.
Zhang T, Wang H, Jia J, Cui X, Li Q, Zhu G. Syntheses and pharmacokinetics properties of an iloperidone pharmaceutical cocrystal. Inorg Chem Commun. 2014;39:144–6.
Parikh K, Sawant K. Comparative study for optimization of pharmaceutical self-emulsifying pre-concentrate by design of experiment and artificial neural network. AAPS PharmSciTech. 2018;19(7):3311–21.
Saha P, Verma S, Das P. Sublingual drug delivery: an indication of potential alternative route. Int J Curr Pharm Res. 2017;9(6):5. https://doi.org/10.22159/ijcpr.2017v9i6.23436.
Sah S, Badola A, Kothiyal P. Sublingual tablets: an overview. Indian J Pharm Biol Res. 2016;4(2):20–6. https://doi.org/10.30750/ijpbr.4.2.3.
Haque S. Significance of fast dissolving oral films and its novel approach towards drug delivery—a review. World J Pharm Res. 2017:237–52. https://doi.org/10.20959/wjpr20176-8441.
Schizophrenia [Internet]. Who.int. 2020 [cited 25 May 2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
Espinoza R. Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets. Int J Pharm. 2000;201(2):165–73. https://doi.org/10.1016/s0378-5173(00)00406-3.
Tran T, Tran P, Choi H, Han H, Lee B. The roles of acidifiers in solid dispersions and physical mixtures. Int J Pharm. 2010;384(1–2):60–6. https://doi.org/10.1016/j.ijpharm.2009.09.039.
Zannou E, Ji Q, Joshi Y, Serajuddin A. Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form. Int J Pharm. 2007;337(1–2):210–8. https://doi.org/10.1016/j.ijpharm.2007.01.005.
Ramadhani N, Shabir M, McConville C. Preparation and characterization of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water-soluble drug disulfiram. Int J Pharm. 2014;475(1–2):514–22. https://doi.org/10.1016/j.ijpharm.2014.09.013.
Li J, Liu P, Liu J, Zhang W, Yang J, Fan Y. Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;80(2):426–32. https://doi.org/10.1016/j.ejpb.2011.11.003.
Bajracharya R, Lee S, Song J, Kim M, Lee K, Han H. Development of a ternary solid dispersion formulation of LW6 to improve the in vivo activity as a BCRP inhibitor: preparation and in vitro/in vivo characterization. Pharmaceutics. 2019;11(5):206. https://doi.org/10.3390/pharmaceutics11050206.
Demirel M, Buyukkoroglu G, Sırmagul B, Kalava B, Ozturk N, Yazan Y. Enhanced bioavailability of cinnarizine using solid dispersion: in vitro and in vivo evaluation. Curr Drug Ther. 2015;9(4):294–301. https://doi.org/10.2174/1574885510999150430154350.
Wairkar S, Gaud R, Jadhav N. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation. J Pharm Pharmacol. 2017;69(9):1099–109. https://doi.org/10.1111/jphp.12756.
Shutdown of European Pharmacopoeia 9th Edition | EDQM - European Directorate for the Quality of Medicines [Internet]. Online6.edqm.eu. 2020 [cited 20 August 2019]. Available from: http://online6.edqm.eu/ep802/.
Indian pharmacopoeia 2018, 235, 546, 2274, 2275.
Choi JS, Byeon JC, Park JS. Naftopidil-fumaric acid interaction in a solid dispersion system: improving the dissolution rate and oral absorption of naftopidil in rats. Mater Sci Eng C. 2019;95:264e274–115. https://doi.org/10.1016/j.ajps.2018.02.007.
Sayed S, Howida K, Magdy Ibrahim M, Mohamed F. Fastdissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation. Mol Pharm. 2013;10(8):2942–7. https://doi.org/10.1021/mp4000713.
Rachid O, Mutasem R, Estelle R, Keith J. Rapidlydisintegrating sublingual tablets of epinephrine: role of nonmedicinal ingredients in formulation development. Eur J Pharm Biopharm. 2012;82(3):598–604. https://doi.org/10.1016/j.ejpb.2012.05.020.
Ahmed ED, Basalious EB, Abdelmalak NS. Bio enhanced sublingual tablet of drug with limited permeability using novel surfactant binder and microencapsulated polysorbate: in vitro/in vivo evaluation. Eur J Pharm Biopharm. 2015;94:386–92.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Highlights
• Binary and ternary complexes of Ilo were formulated.
• Kolliphor P-188 and tartaric acid were optimized as a polymer and an auxiliary agent.
• Tartaric acid accelerated the dissolution efficiency of the drug due to pH change.
• DC tablets showed ≥ 80% release within 5 min for 12 mg, maximum strength.
Rights and permissions
About this article
Cite this article
Pawar, A., Londhe, V.Y. & Bhadale, R.S. Formulation and Characterization of Sublingual Tablets of Iloperidone Prepared by Microenvironmental pH Regulated Approach. J Pharm Innov 17, 104–110 (2022). https://doi.org/10.1007/s12247-020-09502-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12247-020-09502-9